StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)

Close on Nov 18, 2026Market cap $528.94MP/E –Yield –

Myriad Genetics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Myriad Genetics's operating income for the twelve months ending Jun 30, 2026 was -$98.60M. For fiscal 2025 it was -$387.20M. The highest annual figure on record is $274.40M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$387.20M–
FY2024Dec 31, 2024-$123.50M–
FY2023Dec 31, 2023-$257.40M–
FY2022Dec 31, 2022-$140.60M–
FY2020Jun 30, 2020-$231.70M-3148.7%
FY2019Jun 30, 2019$7.60M-93.8%
FY2018Jun 30, 2018$121.90M+177.0%
FY2017Jun 30, 2017$44.00M-71.3%
FY2016Jun 30, 2016$153.40M+14.8%
FY2015Jun 30, 2015$133.60M-51.3%
FY2014Jun 30, 2014$274.40M+20.4%
FY2013Jun 30, 2013$228.00M+26.4%
FY2012Jun 30, 2012$180.32M+14.3%
FY2011Jun 30, 2011$157.78M+16.8%
FY2010Jun 30, 2010$135.08M+6.8%
FY2009Jun 30, 2009$126.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$38.90M–
Q1 FY2026CQ1 2026Mar 31, 2026-$30.70M–
Q4 FY2025CQ4 2025Dec 31, 2025-$5.70M–
Q3 FY2025CQ3 2025Sep 30, 2025-$23.30M–
Q2 FY2025CQ2 2025Jun 30, 2025-$329.20M–
Q1 FY2025CQ1 2025Mar 31, 2025-$29.00M–
Q4 FY2024CQ4 2024Dec 31, 2024-$39.00M–
Q3 FY2024CQ3 2024Sep 30, 2024-$20.00M–
Q2 FY2024CQ2 2024Jun 30, 2024-$36.50M–
Q1 FY2024CQ1 2024Mar 31, 2024-$27.90M–
Q4 FY2023CQ4 2023Dec 31, 2023-$31.40M–
Q3 FY2023CQ3 2023Sep 30, 2023-$60.10M–
Q2 FY2023CQ2 2023Jun 30, 2023-$113.70M–
Q1 FY2023CQ1 2023Mar 31, 2023-$52.20M–
Q4 FY2022CQ4 2022Dec 31, 2022-$52.20M–
Q3 FY2022CQ3 2022Sep 30, 2022-$45.00M–
Q2 FY2022CQ2 2022Jun 30, 2022-$17.80M–
Q1 FY2022CQ1 2022Mar 31, 2022-$25.60M–
Q4 FY2020CQ2 2020Jun 30, 2020-$68.30M–
Q3 FY2020CQ1 2020Mar 31, 2020-$133.70M-2366.1%
Q2 FY2020CQ4 2019Dec 31, 2019-$8.80M-244.3%
Q1 FY2020CQ3 2019Sep 30, 2019-$20.90M-1841.7%
Q4 FY2019CQ2 2019Jun 30, 2019-$5.60M-131.5%
Q3 FY2019CQ1 2019Mar 31, 2019$5.90M-57.2%
Q2 FY2019CQ4 2018Dec 31, 2018$6.10M-3.2%
Q1 FY2019CQ3 2018Sep 30, 2018$1.20M-98.6%
Q4 FY2018CQ2 2018Jun 30, 2018$17.80M-5.8%
Q3 FY2018CQ1 2018Mar 31, 2018$13.80M+150.9%
Q2 FY2018CQ4 2017Dec 31, 2017$6.30M-63.4%
Q1 FY2018CQ3 2017Sep 30, 2017$84.00M+1083.1%
Q4 FY2017CQ2 2017Jun 30, 2017$18.90M-14.9%
Q3 FY2017CQ1 2017Mar 31, 2017$5.50M-87.1%
Q2 FY2017CQ4 2016Dec 31, 2016$17.20M-61.9%
Q1 FY2017CQ3 2016Sep 30, 2016$7.10M-83.6%
Q4 FY2016CQ2 2016Jun 30, 2016$22.20M-37.6%
Q3 FY2016CQ1 2016Mar 31, 2016$42.60M+19.3%
Q2 FY2016CQ4 2015Dec 31, 2015$45.20M–
Q1 FY2016CQ3 2015Sep 30, 2015$43.30M–
Q4 FY2015CQ2 2015Jun 30, 2015$35.60M–
Q3 FY2015CQ1 2015Mar 31, 2015$35.70M–

More Myriad Genetics figures

See a number that looks wrong?